Medicines Discovery Catapult a national Life Science service
Source: https://md.catapult.org.uk
Archived: 2026-04-23 16:40
Medicines Discovery Catapult a national Life Science service
Transforming innovative drug
discovery into life-changing medicines
A Life Science service driving game-changing global breakthroughs and improving patients’ lives. Here to make sure your next move counts.
Drug discovery
Tackling complex global challenges,
addressing unmet patient needs
Creating momentum by mobilising the right people and partnerships, stimulating innovation through our national programmes.
Global challenges
Impacting the Life Sciences sector,
improving the health of our society
We work with the most innovative entrepreneurs on the brink of discovery, helping them turn their vision into an effective business plan and giving them a greater chance of commercial success.
What we do
Medicines Discovery Catapult de-risks new medicine discovery, provides access to technologies, skills, and knowledge, and runs impactful R&D partnerships.
We connect innovators to a broad and diverse support network for the next step of their journey. We provide insights, critical commentary, and guidance for the sector and the development of new policy.
We are part of the
Innovate UK
Catapult Network
, co-funded by industry and government. We are not-for-profit and commercially driven. We reinvest time, money, resources and discoveries back into Life Sciences to help our sector thrive.
Find out more
The impact
we have made
We have supported 389 innovators, helping them raise over £1.8bn of R&D investment and supporting them to take five new drugs to clinical trials.
Our impact
£1.8bn
SME funding secured post-engagement
£134.2m
grant income raised in collaboration
5
compounds supported into the clinic
3
partner products progressed to market
12
assays supporting clinical development
389
organisations supported
Drug discovery at Medicines Discovery Catapult
We de-risk new medicine discovery and provide access to technologies, skills, and knowledge.
Our experts apply the very best new laboratory technology to validate ideas. We help build long-term success to reshape drug discovery.
We use our expertise and networks to design robust
R&D roadmaps
for the quickest, safest route to patients and commercial success.
We use our global connections to create momentum for innovators so they can access broader support, secure investment, and get to market.
Explore more
See how we have helped innovators
Partnering with the MDC has been transformative for Innate Repair. Their world-class expertise and facilities allowed us to conduct complex oncology experiments quickly, cost-effectively, and to the highest scientific standards. MDC is an exceptional partner for any biotech aiming to accelerate innovation.
Innate Repair
Medicines Discovery Catapult R&D consulting provided Apeikon Therapeutics with clear direction and structured guidance, helping us define a robust product development plan. Their expertise streamlined our vision into actionable steps, accelerating progress and ensuring strategic alignment.
Apeikon Therapeutics
CPSA is an ingenious extension of the target engagement toolbox. It is easier to upscale and control in high throughput screening applications than currently available methods. With exemplary support from MDC we have smoothly incorporated it into our Drug Discovery pipeline.
Selvita
MDC’s R&D consulting has been transformative, refining our HT8457S strategy with scientific rigour, identifying and mitigating risks, and strengthening our business model, significantly enhancing Haiku’s credibility.
Haiku Therapeutics
The partnership with MDC has allowed us to secure multiple Innovate UK grants and utilise capabilities such as state-of-the-art PET, which aren’t available elsewhere.
Alchemab Therapeutics
For the first time, we have been able to generate a map of lung fibrosis in 3D at the tissue scale. Collaborating with MDC has been key to its success. Their expertise has supported the successful integration of state-of-the-art technologies, establishing a valuable new resource for the lung fibrosis community.
University of Southampton
Working with MDC allowed us to visualise drug distribution in the brain with a level of clarity we hadn’t achieved before. Their expertise in DESI-MS and willingness to design a project that met our demands provided powerful insights into diffusion patterns, giving us confidence in our compound’s delivery.
TargTex
We worked with the Mass Spectrometry team at MDC to help set up and run a complex biochemical assay. The project was technically demanding, but the deep expertise, knowledge and collaborative approach allowed the team to troubleshoot the many challenges and successfully deliver a viable approach.
Oppilotech
The team at MDC shares our passion for bringing forward innovative medicines, pioneering new technologies, and operating with data-driven flexibility. They have been integral to our project success and possess unique capabilities to support later-stage candidate selection. A truly valued collaborator and dependable partner.
Artbio
Elasmogen was impressed by the quality and rapid delivery timelines for our radiopharmaceutical dosimetry data. There was good interactivity in this project, and we are happy to recommend this service.
Elasmogen
Our collaboration with Medicines Discovery Catapult will not only enable us to engage with the wider scientific community but will also allow us to unlock the potential of Acoustic Mass Spectrometry within drug discovery.
Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca
It’s been absolutely amazing working with MDC and the team.
LUNAC Therapeutics
MDC supported us in developing a therapeutic for Huntington’s Disease through antibody characterisation, iPSC model development, biodistribution studies, imaging and neurodegenerative expertise.
Alchemab Therapeutics
We worked together with MDC on a very challenging and demanding project. The MDC team’s expertise in MSI, commitment and flexibility were key to a successful collaboration and reaching our objectives.
TargTex
MDC are as involved in our project as the founding team, going above and beyond what I expected. I recommend them to new ventures starting out; even if you don’t know exactly what you need, the team can work with you to achieve some phenomenal results.
KLAS Therapeutics
Working with MDC has provided expertise and intellectual input. It has also enabled access to a wider network of companies providing specialist services.
N4 Pharma
By tapping into MDC’s unique drug development expertise and facilities, we are confident we will accelerate the preclinical development of our drug delivery system and its commercialisation.
Sixfold Bioscience
It has been a pleasure working with MDC as their scientists are pleasant and have a broad range of talents.
Importantly for projects like ours, they openly and professionally exchange ideas with SMi’s scientific team and keep us abreast of their research developments.
SMi Systems
It has been great to access the Artificial Intelligence expertise at Medicines Discovery Catapult.
The team has taken an innovative approach that adds value to our product and will benefit our customers.
BioAscent
As an SME, working with MDC allows us access to scientific know-how and
in vivo
imaging techniques that would be impossible through any other route. The closeness, timeliness and flexibility of the collaboration significantly accelerated our ability to develop the product.
Xerion Healthcare
We have collaborated with MDC for three years, and it continues to provide valuable and high-quality data on our molecules. MDC’s input has directly impacted operational and strategic decisions for our projects and allowed us to move forward with our clinical studies.
Revolo Biotherapeutics
For early-stage SMEs in this space, I thoroughly recommend engaging with MDC, who have the end-to-end knowledge in complex medicines, can support your in-house team and provide access to key equipment that start-ups may not have.
pHion Therapeutics
Tackling the complex
global
challenges facing patients
We tackle global challenges in Life Sciences by stimulating innovation and addressing unmet patient need through our national programmes.
We connect patient communities, charities, global biotechs, academia, and pharma to accelerate discoveries and improve lives.
Find out more
How we have helped
Read our stories showcasing how we have helped drug discovery SMEs and innovators.
Connecting the UK Life Sciences ecosystem
Explore more
Addressing unmet patient needs
Explore more
Enabling access to essential technologies and skills
Explore more
Leading the conversation for drug discovery sector
Explore more
Advising and supporting innovators,
investing in exceptional science
We can support you with our R&D consultancy, Collaborative R&D services, and grant support.
Learn more
Latest news and events
All
News
Events
Blogs
Reports
Recordings
Publications
News, blogs, events, reports and more. Our latest press releases, media appearances, events and news commentary.
Our latest press releases, media appearances and news commentary.
Take a look at the events and global conferences we are speaking at.
Written by our own experts or members of the drug discovery community.
Recent scientific reports featuring contributions from our scientists and members of the drug discovery community.
Our latest recordings and webinars showcasing our innovative scientific collaborations.
Recent articles and papers featuring contributions from our scientists.
All
News
Events
Blogs
Reports
Recordings
Publications
Publications
17 April 2026
End-to-end in vitro and in vivo evaluation of radiopharmaceuticals in patient-derived models
Read more
Publications
09 April 2026
Biomarker Profiling of Radiation and DDR Inhibitor Combinations in LNCaP Xenografts
Read more
Events
03 May 2026
Swiss Biotech Day 2026
Find out more
News
17 March 2026
New Medicines Discovery Catapult and CPI project boosts UK capability in next-generation RNA medicines
Read more
Blogs
13 March 2026
What clinicians need from a preclinical radiopharmaceutical data package
Read more
News
13 March 2026
Medicines Discovery Catapult energises over 600 young ‘Medicine Makers’ for British Science Week
Read more
Events
20 April 2026
BNMS 2026
Find out more
Events
17 April 2026
Cancer Research Meeting – San Diego
Find out more
Events
17 March 2026
RNA Leaders Europe 2026
Find out more
Publications
25 February 2026
A human iPSC platform for studying pathogenic protein aggregation in neurodegeneration
Read more
Publications
25 February 2026
Development of CNS model for neurodegenerative drug discovery using 3D printed human iPSC-derived cells
Read more
Publications
25 February 2026
Development of a human reactive astrocyte platform for drug discovery
Read more
Publications
25 February 2026
Use of Innovative Multi-Omics Platforms to Study Neurodegenerative Disease
Read more
Events
23 March 2026
Bio-Europe Spring 2026
Find out more
News
23 February 2026
From models to medicines: ABPI and NC3Rs release landmark report
Read more
Events
12 February 2026
Webinar: The frontier AI landscape
Find out more
Events
18 February 2026
AMR 2026
Find out more
Events
04 February 2026
The Royal Society – A human focus for 21st century life sciences
Find out more
Events
04 February 2026
MDC Drop-in clinic at Sheffield Technology Parks
Find out more
Blogs
29 January 2026
How robust preclinical data can de-risk radiopharmaceutical investment
Read more
News
12 January 2026
Professor Chris Molloy, Chief Executive Officer of Medicines Discovery Catapult, steps down after ten years at the helm
Read more
Blogs
19 December 2025
Better tools, better medicines: deploying CRISPR-Cas9 genome engineering in drug discovery
Read more
Blogs
19 December 2025
Rupturing endosomes are not created equal
Read more
Events
07 February 2026
SLAS 2026 International Conference and Exhibition
Find out more
News
18 November 2025
UK nuclear revolution powers next-generation precision cancer therapies
Read more
News
11 November 2025
£15.9m Investment to Power Next-Generation Human Disease Modelling
Read more
Publications
20 October 2025
R&D Consulting at Medicines Discovery Catapult
Read more
Publications
20 October 2025
Application of Spatial Biology in the Evaluation of a Photodynamic Therapeutic Candidate in Melanoma Treatment
Read more
Events
10 November 2025
TRP Targeted Radiopharmaceuticals Summit Europe
Find out more
News
07 October 2025
Medicines Discovery Catapult Announced as Newest Innovate UK Knowledge Base, Supporting Life Science Sector Growth
Read more
News
01 October 2025
PACE Announces £6 Million Funding for Antibacterial Treatment Innovations to Fill Critical Gap in R&D Pipeline
Read more
Blogs
24 September 2025
Human Models for Human Pain: iPSC-Derived Sensory Neurons for Medicines Discovery
Read more
Events
13 November 2025
RNID Hearing Therapeutics Summit 2025
Find out more
News
11 September 2025
Medicines Discovery Catapult and Crown Bioscience Form Strategic Global Alliance for Radiopharmaceutical Innovation
Read more
Events
03 November 2025
BIO-Europe Autumn
Find out more
Events
21 October 2025
Drug Discovery 2025
Find out more
Events
04 October 2025
EANM 2025
Find out more
News
04 September 2025
Breakthrough Glioblastoma Treatments Move Closer to Patients as Medicines Discovery Catapult and King’s College London Secure Brain Tumour Charity Funding
Read more
Reports
04 September 2025
Medicines Discovery Catapult 2024/25 Annual Report
Read more
News
04 September 2025
MDC Annual Report Published, For the Year Ended 31 March 2025
Read more
Events
30 September 2025
Biomarkers & Precision Medicine
Find out more
Events
22 September 2025
Discovery on Target
Find out more
News
20 August 2025
National PET Imaging Platform Announces University of Cambridge as Newest Site to Receive Total-Body PET Scanner
Read more
Blogs
18 July 2025
Enhancing Radiopharmaceutical Development with Clinically Relevant PDX Models
Read more
News
16 July 2025
£1m Funding for Innovative Drug Discovery Projects in Collaboration with Medicines Discovery Catapult
Read more
Publications
27 June 2025
MDC Chemical Protein Stability Assay (CPSA) a novel target engagement approach
Read more
News
23 June 2025
Launch of New Total-Body Scanner Extends UK’s World-Class Imaging Platform to Scotland
Read more
News
03 June 2025
Medicines Discovery Catapult and the Francis Crick Institute Partner to Support KQ Labs, a Leading Accelerator for Life Sciences Innovators
Read more
Publications
28 May 2025
Use of microfluidics technology to model α-synuclein aggregation and seeding in Parkinson’s disease in vitro
Read more
News
27 May 2025
Selvita Acquires License for Medicines Discovery Catapult’s Patented Target Engagement Technology
Read more
Publications
23 May 2025
BNA Poster 2025 Reactive Astrocytes MDC ALZ
Read more
Publications
21 March 2025
Use of innovative multi-omics platforms to study neurodegenerative disease
Read more
News
17 March 2025
MDC achieves ISO 45001 health and safety standard
Read more
News
07 March 2025
Medicines Discovery Catapult Wins Bionow Business Support Award
Read more
Blogs
03 March 2025
Preclinical to Clinical: The Power of Using Multiple Models and Technologies for Neuroinflammation Drug Discovery
Read more
News
18 February 2025
Commercialisation Pathway Simplified with New Regulatory Roadmap for RNA Therapeutics and Vaccines
Read more
News
12 February 2025
New Funding Available to Mental Health Drug Discovery Innovators
Read more
News
30 January 2025
Scientific Experts Join Medicines Discovery Catapult’s Board of Directors
Read more
Reports
30 January 2025
Regulatory Requirements for Nanotechnology-Based RNA Vaccines Therapeutics
Read more
News
17 January 2025
MDC Publishes First Year of ESG Progress
Read more
News
16 January 2025
Turning Nuclear Waste into Breakthrough Cancer Treatments
Read more
News
13 January 2025
Medicines Discovery Catapult Strengthens Senior Leadership Team with Two Executive Appointments
Read more
News
28 November 2024
Patient and Ministers Unveil NPIP’s First Total-Body PET Scanner as London Site Becomes Operational
Read more
News
21 November 2024
CF AMR Syndicate Wins Most Impactful Industry Collaboration of the Year Award
Read more
News
26 September 2024
Global AMR Challenge Receives a £5m Boost to Drive Diagnostics Innovation
Read more
News
24 September 2024
CF AMR Syndicate Announces First Awardees of £3m Collaborative Drug Discovery Programme
Read more
News
04 September 2024
New Gene Editing License Agreement Set to Unlock Deeper Drug Discovery Insights
Read more
News
02 August 2024
MDC Annual Report Published, For the Year Ended 31 March 2024
Read more
Reports
01 August 2024
Medicines Discovery Catapult 2023/24 Annual Report
Read more
Blogs
29 July 2024
Unleashing the Potential of Human Tissue Biomarker Analysis with Spatial Epigenetic Profiling
Read more
Blogs
25 July 2024
Biomarkers in neurodegeneration
Read more
Blogs
24 July 2024
Access to Labs
Read more
Blogs
11 July 2024
MDC Connects 2024 Blog Post: IP Protection Strategy: The University Technology Transfer Perspective
Read more
Blogs
10 July 2024
MDC Connects 2024 Blog Post: Options for Commercialising Innovation
Read more
Blogs
03 July 2024
Accessing the Skills for Successful Drug Discovery
Read more
Sign up for our
email newsletter
Get the latest news, blogs, reports, publications and upcoming events direct to your inbox every month.
Partner with us and make sure your next move counts
See how we can help support you with your next drug discovery project.
Speak to us
Medicines Discovery Catapult
Transforming innovative drug
discovery into life-changing medicines
A Life Science service driving game-changing global breakthroughs and improving patients’ lives. Here to make sure your next move counts.
Drug discovery
Tackling complex global challenges,
addressing unmet patient needs
Creating momentum by mobilising the right people and partnerships, stimulating innovation through our national programmes.
Global challenges
Impacting the Life Sciences sector,
improving the health of our society
We work with the most innovative entrepreneurs on the brink of discovery, helping them turn their vision into an effective business plan and giving them a greater chance of commercial success.
What we do
Medicines Discovery Catapult de-risks new medicine discovery, provides access to technologies, skills, and knowledge, and runs impactful R&D partnerships.
We connect innovators to a broad and diverse support network for the next step of their journey. We provide insights, critical commentary, and guidance for the sector and the development of new policy.
We are part of the
Innovate UK
Catapult Network
, co-funded by industry and government. We are not-for-profit and commercially driven. We reinvest time, money, resources and discoveries back into Life Sciences to help our sector thrive.
Find out more
The impact
we have made
We have supported 389 innovators, helping them raise over £1.8bn of R&D investment and supporting them to take five new drugs to clinical trials.
Our impact
£1.8bn
SME funding secured post-engagement
£134.2m
grant income raised in collaboration
5
compounds supported into the clinic
3
partner products progressed to market
12
assays supporting clinical development
389
organisations supported
Drug discovery at Medicines Discovery Catapult
We de-risk new medicine discovery and provide access to technologies, skills, and knowledge.
Our experts apply the very best new laboratory technology to validate ideas. We help build long-term success to reshape drug discovery.
We use our expertise and networks to design robust
R&D roadmaps
for the quickest, safest route to patients and commercial success.
We use our global connections to create momentum for innovators so they can access broader support, secure investment, and get to market.
Explore more
See how we have helped innovators
Partnering with the MDC has been transformative for Innate Repair. Their world-class expertise and facilities allowed us to conduct complex oncology experiments quickly, cost-effectively, and to the highest scientific standards. MDC is an exceptional partner for any biotech aiming to accelerate innovation.
Innate Repair
Medicines Discovery Catapult R&D consulting provided Apeikon Therapeutics with clear direction and structured guidance, helping us define a robust product development plan. Their expertise streamlined our vision into actionable steps, accelerating progress and ensuring strategic alignment.
Apeikon Therapeutics
CPSA is an ingenious extension of the target engagement toolbox. It is easier to upscale and control in high throughput screening applications than currently available methods. With exemplary support from MDC we have smoothly incorporated it into our Drug Discovery pipeline.
Selvita
MDC’s R&D consulting has been transformative, refining our HT8457S strategy with scientific rigour, identifying and mitigating risks, and strengthening our business model, significantly enhancing Haiku’s credibility.
Haiku Therapeutics
The partnership with MDC has allowed us to secure multiple Innovate UK grants and utilise capabilities such as state-of-the-art PET, which aren’t available elsewhere.
Alchemab Therapeutics
For the first time, we have been able to generate a map of lung fibrosis in 3D at the tissue scale. Collaborating with MDC has been key to its success. Their expertise has supported the successful integration of state-of-the-art technologies, establishing a valuable new resource for the lung fibrosis community.
University of Southampton
Working with MDC allowed us to visualise drug distribution in the brain with a level of clarity we hadn’t achieved before. Their expertise in DESI-MS and willingness to design a project that met our demands provided powerful insights into diffusion patterns, giving us confidence in our compound’s delivery.
TargTex
We worked with the Mass Spectrometry team at MDC to help set up and run a complex biochemical assay. The project was technically demanding, but the deep expertise, knowledge and collaborative approach allowed the team to troubleshoot the many challenges and successfully deliver a viable approach.
Oppilotech
The team at MDC shares our passion for bringing forward innovative medicines, pioneering new technologies, and operating with data-driven flexibility. They have been integral to our project success and possess unique capabilities to support later-stage candidate selection. A truly valued collaborator and dependable partner.
Artbio
Elasmogen was impressed by the quality and rapid delivery timelines for our radiopharmaceutical dosimetry data. There was good interactivity in this project, and we are happy to recommend this service.
Elasmogen
Our collaboration with Medicines Discovery Catapult will not only enable us to engage with the wider scientific community but will also allow us to unlock the potential of Acoustic Mass Spectrometry within drug discovery.
Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca
It’s been absolutely amazing working with MDC and the team.
LUNAC Therapeutics
MDC supported us in developing a therapeutic for Huntington’s Disease through antibody characterisation, iPSC model development, biodistribution studies, imaging and neurodegenerative expertise.
Alchemab Therapeutics
We worked together with MDC on a very challenging and demanding project. The MDC team’s expertise in MSI, commitment and flexibility were key to a successful collaboration and reaching our objectives.
TargTex
MDC are as involved in our project as the founding team, going above and beyond what I expected. I recommend them to new ventures starting out; even if you don’t know exactly what you need, the team can work with you to achieve some phenomenal results.
KLAS Therapeutics
Working with MDC has provided expertise and intellectual input. It has also enabled access to a wider network of companies providing specialist services.
N4 Pharma
By tapping into MDC’s unique drug development expertise and facilities, we are confident we will accelerate the preclinical development of our drug delivery system and its commercialisation.
Sixfold Bioscience
It has been a pleasure working with MDC as their scientists are pleasant and have a broad range of talents.
Importantly for projects like ours, they openly and professionally exchange ideas with SMi’s scientific team and keep us abreast of their research developments.
SMi Systems
It has been great to access the Artificial Intelligence expertise at Medicines Discovery Catapult.
The team has taken an innovative approach that adds value to our product and will benefit our customers.
BioAscent
As an SME, working with MDC allows us access to scientific know-how and
in vivo
imaging techniques that would be impossible through any other route. The closeness, timeliness and flexibility of the collaboration significantly accelerated our ability to develop the product.
Xerion Healthcare
We have collaborated with MDC for three years, and it continues to provide valuable and high-quality data on our molecules. MDC’s input has directly impacted operational and strategic decisions for our projects and allowed us to move forward with our clinical studies.
Revolo Biotherapeutics
For early-stage SMEs in this space, I thoroughly recommend engaging with MDC, who have the end-to-end knowledge in complex medicines, can support your in-house team and provide access to key equipment that start-ups may not have.
pHion Therapeutics
Tackling the complex
global
challenges facing patients
We tackle global challenges in Life Sciences by stimulating innovation and addressing unmet patient need through our national programmes.
We connect patient communities, charities, global biotechs, academia, and pharma to accelerate discoveries and improve lives.
Find out more
How we have helped
Read our stories showcasing how we have helped drug discovery SMEs and innovators.
Connecting the UK Life Sciences ecosystem
Explore more
Addressing unmet patient needs
Explore more
Enabling access to essential technologies and skills
Explore more
Leading the conversation for drug discovery sector
Explore more
Advising and supporting innovators,
investing in exceptional science
We can support you with our R&D consultancy, Collaborative R&D services, and grant support.
Learn more
Latest news and events
All
News
Events
Blogs
Reports
Recordings
Publications
News, blogs, events, reports and more. Our latest press releases, media appearances, events and news commentary.
Our latest press releases, media appearances and news commentary.
Take a look at the events and global conferences we are speaking at.
Written by our own experts or members of the drug discovery community.
Recent scientific reports featuring contributions from our scientists and members of the drug discovery community.
Our latest recordings and webinars showcasing our innovative scientific collaborations.
Recent articles and papers featuring contributions from our scientists.
All
News
Events
Blogs
Reports
Recordings
Publications
Publications
17 April 2026
End-to-end in vitro and in vivo evaluation of radiopharmaceuticals in patient-derived models
Read more
Publications
09 April 2026
Biomarker Profiling of Radiation and DDR Inhibitor Combinations in LNCaP Xenografts
Read more
Events
03 May 2026
Swiss Biotech Day 2026
Find out more
News
17 March 2026
New Medicines Discovery Catapult and CPI project boosts UK capability in next-generation RNA medicines
Read more
Blogs
13 March 2026
What clinicians need from a preclinical radiopharmaceutical data package
Read more
News
13 March 2026
Medicines Discovery Catapult energises over 600 young ‘Medicine Makers’ for British Science Week
Read more
Events
20 April 2026
BNMS 2026
Find out more
Events
17 April 2026
Cancer Research Meeting – San Diego
Find out more
Events
17 March 2026
RNA Leaders Europe 2026
Find out more
Publications
25 February 2026
A human iPSC platform for studying pathogenic protein aggregation in neurodegeneration
Read more
Publications
25 February 2026
Development of CNS model for neurodegenerative drug discovery using 3D printed human iPSC-derived cells
Read more
Publications
25 February 2026
Development of a human reactive astrocyte platform for drug discovery
Read more
Publications
25 February 2026
Use of Innovative Multi-Omics Platforms to Study Neurodegenerative Disease
Read more
Events
23 March 2026
Bio-Europe Spring 2026
Find out more
News
23 February 2026
From models to medicines: ABPI and NC3Rs release landmark report
Read more
Events
12 February 2026
Webinar: The frontier AI landscape
Find out more
Events
18 February 2026
AMR 2026
Find out more
Events
04 February 2026
The Royal Society – A human focus for 21st century life sciences
Find out more
Events
04 February 2026
MDC Drop-in clinic at Sheffield Technology Parks
Find out more
Blogs
29 January 2026
How robust preclinical data can de-risk radiopharmaceutical investment
Read more
News
12 January 2026
Professor Chris Molloy, Chief Executive Officer of Medicines Discovery Catapult, steps down after ten years at the helm
Read more
Blogs
19 December 2025
Better tools, better medicines: deploying CRISPR-Cas9 genome engineering in drug discovery
Read more
Blogs
19 December 2025
Rupturing endosomes are not created equal
Read more
Events
07 February 2026
SLAS 2026 International Conference and Exhibition
Find out more
News
18 November 2025
UK nuclear revolution powers next-generation precision cancer therapies
Read more
News
11 November 2025
£15.9m Investment to Power Next-Generation Human Disease Modelling
Read more
Publications
20 October 2025
R&D Consulting at Medicines Discovery Catapult
Read more
Publications
20 October 2025
Application of Spatial Biology in the Evaluation of a Photodynamic Therapeutic Candidate in Melanoma Treatment
Read more
Events
10 November 2025
TRP Targeted Radiopharmaceuticals Summit Europe
Find out more
News
07 October 2025
Medicines Discovery Catapult Announced as Newest Innovate UK Knowledge Base, Supporting Life Science Sector Growth
Read more
News
01 October 2025
PACE Announces £6 Million Funding for Antibacterial Treatment Innovations to Fill Critical Gap in R&D Pipeline
Read more
Blogs
24 September 2025
Human Models for Human Pain: iPSC-Derived Sensory Neurons for Medicines Discovery
Read more
Events
13 November 2025
RNID Hearing Therapeutics Summit 2025
Find out more
News
11 September 2025
Medicines Discovery Catapult and Crown Bioscience Form Strategic Global Alliance for Radiopharmaceutical Innovation
Read more
Events
03 November 2025
BIO-Europe Autumn
Find out more
Events
21 October 2025
Drug Discovery 2025
Find out more
Events
04 October 2025
EANM 2025
Find out more
News
04 September 2025
Breakthrough Glioblastoma Treatments Move Closer to Patients as Medicines Discovery Catapult and King’s College London Secure Brain Tumour Charity Funding
Read more
Reports
04 September 2025
Medicines Discovery Catapult 2024/25 Annual Report
Read more
News
04 September 2025
MDC Annual Report Published, For the Year Ended 31 March 2025
Read more
Events
30 September 2025
Biomarkers & Precision Medicine
Find out more
Events
22 September 2025
Discovery on Target
Find out more
News
20 August 2025
National PET Imaging Platform Announces University of Cambridge as Newest Site to Receive Total-Body PET Scanner
Read more
Blogs
18 July 2025
Enhancing Radiopharmaceutical Development with Clinically Relevant PDX Models
Read more
News
16 July 2025
£1m Funding for Innovative Drug Discovery Projects in Collaboration with Medicines Discovery Catapult
Read more
Publications
27 June 2025
MDC Chemical Protein Stability Assay (CPSA) a novel target engagement approach
Read more
News
23 June 2025
Launch of New Total-Body Scanner Extends UK’s World-Class Imaging Platform to Scotland
Read more
News
03 June 2025
Medicines Discovery Catapult and the Francis Crick Institute Partner to Support KQ Labs, a Leading Accelerator for Life Sciences Innovators
Read more
Publications
28 May 2025
Use of microfluidics technology to model α-synuclein aggregation and seeding in Parkinson’s disease in vitro
Read more
News
27 May 2025
Selvita Acquires License for Medicines Discovery Catapult’s Patented Target Engagement Technology
Read more
Publications
23 May 2025
BNA Poster 2025 Reactive Astrocytes MDC ALZ
Read more
Publications
21 March 2025
Use of innovative multi-omics platforms to study neurodegenerative disease
Read more
News
17 March 2025
MDC achieves ISO 45001 health and safety standard
Read more
News
07 March 2025
Medicines Discovery Catapult Wins Bionow Business Support Award
Read more
Blogs
03 March 2025
Preclinical to Clinical: The Power of Using Multiple Models and Technologies for Neuroinflammation Drug Discovery
Read more
News
18 February 2025
Commercialisation Pathway Simplified with New Regulatory Roadmap for RNA Therapeutics and Vaccines
Read more
News
12 February 2025
New Funding Available to Mental Health Drug Discovery Innovators
Read more
News
30 January 2025
Scientific Experts Join Medicines Discovery Catapult’s Board of Directors
Read more
Reports
30 January 2025
Regulatory Requirements for Nanotechnology-Based RNA Vaccines Therapeutics
Read more
News
17 January 2025
MDC Publishes First Year of ESG Progress
Read more
News
16 January 2025
Turning Nuclear Waste into Breakthrough Cancer Treatments
Read more
News
13 January 2025
Medicines Discovery Catapult Strengthens Senior Leadership Team with Two Executive Appointments
Read more
News
28 November 2024
Patient and Ministers Unveil NPIP’s First Total-Body PET Scanner as London Site Becomes Operational
Read more
News
21 November 2024
CF AMR Syndicate Wins Most Impactful Industry Collaboration of the Year Award
Read more
News
26 September 2024
Global AMR Challenge Receives a £5m Boost to Drive Diagnostics Innovation
Read more
News
24 September 2024
CF AMR Syndicate Announces First Awardees of £3m Collaborative Drug Discovery Programme
Read more
News
04 September 2024
New Gene Editing License Agreement Set to Unlock Deeper Drug Discovery Insights
Read more
News
02 August 2024
MDC Annual Report Published, For the Year Ended 31 March 2024
Read more
Reports
01 August 2024
Medicines Discovery Catapult 2023/24 Annual Report
Read more
Blogs
29 July 2024
Unleashing the Potential of Human Tissue Biomarker Analysis with Spatial Epigenetic Profiling
Read more
Blogs
25 July 2024
Biomarkers in neurodegeneration
Read more
Blogs
24 July 2024
Access to Labs
Read more
Blogs
11 July 2024
MDC Connects 2024 Blog Post: IP Protection Strategy: The University Technology Transfer Perspective
Read more
Blogs
10 July 2024
MDC Connects 2024 Blog Post: Options for Commercialising Innovation
Read more
Blogs
03 July 2024
Accessing the Skills for Successful Drug Discovery
Read more
Sign up for our
email newsletter
Get the latest news, blogs, reports, publications and upcoming events direct to your inbox every month.
Partner with us and make sure your next move counts
See how we can help support you with your next drug discovery project.
Speak to us
Medicines Discovery Catapult